The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening
- PMID: 20019025
- DOI: 10.1093/eurheartj/ehp539
The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening
Abstract
Aims: We investigated the presence of a clinical diagnosis of hypertrophic cardiomyopathy (HCM) and of risk factors for sudden cardiac death (SCD) at the first cardiological evaluation after predictive genetic testing in asymptomatic carriers of an MYBPC3 gene mutation.
Methods and results: Two hundred and thirty-five mutation carriers were cardiologically evaluated on the presence of HCM and risk factors. A clinical diagnosis of HCM was made in 53 carriers (22.6%). Disease penetrance at 65 years was incomplete for all types of MYBPC3 gene mutations. Women were affected less often than men (15 and 32% respectively, P = 0.003) and disease penetrance was lower in females than in males (13 and 30% at 50 years, respectively, P = 0.024). One risk factor was present in 87 carriers and 9 had two or more risk factors. Twenty-five carriers (11%) with one or more risk factors and manifest HCM could be at risk for SCD.
Conclusion: At first cardiological evaluation almost one-quarter of asymptomatic carriers was diagnosed with HCM. Risk factors for SCD were frequently present and 11% of carriers could be at risk for SCD. Predictive genetic testing in HCM families and frequent cardiological evaluation on the presence of HCM and risk factors for SCD are justified until advanced age.
Similar articles
-
Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.Eur Heart J. 2009 Nov;30(21):2593-8. doi: 10.1093/eurheartj/ehp306. Epub 2009 Aug 6. Eur Heart J. 2009. PMID: 19666645
-
Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy.Eur Heart J. 2011 May;32(9):1161-70. doi: 10.1093/eurheartj/ehr092. Epub 2011 Apr 1. Eur Heart J. 2011. PMID: 21459882
-
Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome.Circ Cardiovasc Genet. 2012 Apr 1;5(2):156-66. doi: 10.1161/CIRCGENETICS.111.960831. Epub 2012 Jan 20. Circ Cardiovasc Genet. 2012. PMID: 22267749
-
[Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].Arch Mal Coeur Vaiss. 1999 Apr;92 Spec No 1:65-73. Arch Mal Coeur Vaiss. 1999. PMID: 10326160 Review. French.
-
Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression.Nat Clin Pract Cardiovasc Med. 2008 Mar;5(3):158-68. doi: 10.1038/ncpcardio1110. Epub 2008 Jan 29. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18227814 Review.
Cited by
-
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. Clin Res Cardiol. 2018. PMID: 28840316 Review.
-
Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes.J Med Genet. 2022 Aug;59(8):768-775. doi: 10.1136/jmedgenet-2021-107774. Epub 2021 Aug 16. J Med Genet. 2022. PMID: 34400558 Free PMC article.
-
Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup.Genet Med. 2018 Jan;20(1):69-75. doi: 10.1038/gim.2017.79. Epub 2017 Jun 22. Genet Med. 2018. PMID: 28640247
-
Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.Pflugers Arch. 2015 Jun;467(6):1303-17. doi: 10.1007/s00424-014-1570-7. Epub 2014 Jul 11. Pflugers Arch. 2015. PMID: 25010737
-
BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants-design and status.Neth Heart J. 2021 Jun;29(6):318-329. doi: 10.1007/s12471-021-01539-w. Epub 2021 Feb 2. Neth Heart J. 2021. PMID: 33532905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources